

Follicular Lymphoma Drugs Industry Research Report 2023

<https://marketpublishers.com/r/F1051D5E19D8EN.html>

Date: August 2023

Pages: 85

Price: US\$ 2,950.00 (Single User License)

ID: F1051D5E19D8EN

Abstracts

Highlights

The global Follicular Lymphoma Drugs market is projected to reach US\$ million by 2029 from an estimated US\$ million in 2023, at a CAGR of % during 2024 and 2029.

North American market for Follicular Lymphoma Drugs is estimated to increase from \$ million in 2023 to reach \$ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.

Asia-Pacific market for Follicular Lymphoma Drugs is estimated to increase from \$ million in 2023 to reach \$ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.

The major global companies of Follicular Lymphoma Drugs include Roche, Gilead Sciences, TG Therapeutics, Bayer, Secura Bio, Epizyme, Eisai, Acrotech Biopharma and Teva, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

The global market for Follicular Lymphoma Drugs in Injection is estimated to increase from \$ million in 2023 to \$ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.

Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Anti-CD20 mAbs, which accounted for % of the global market of Follicular Lymphoma Drugs in 2022, is expected to reach million US\$ by 2029, growing at a revised CAGR of % from 2024 to 2029.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Follicular Lymphoma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Follicular Lymphoma Drugs.

The Follicular Lymphoma Drugs market size, estimations, and forecasts are provided in terms of and revenue (\$ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Follicular Lymphoma Drugs market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Follicular Lymphoma Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Roche

Gilead Sciences

TG Therapeutics

Bayer

Secura Bio

Epizyme

Eisai

Acrotech Biopharma

Teva

Eagle Pharmaceuticals

MundiPharma

Product Type Insights

Global markets are presented by Follicular Lymphoma Drugs type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Follicular Lymphoma Drugs are procured by the companies.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).

Follicular Lymphoma Drugs segment by Type

Anti-CD20 mAbs

Chemotherapy Agents

Kinase Inhibitor

Others

Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).

This report also outlines the market trends of each segment and consumer behaviors impacting the Follicular Lymphoma Drugs market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Follicular Lymphoma Drugs market.

Follicular Lymphoma Drugs Segment by Administration Route

Injection

Oral

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Follicular Lymphoma Drugs market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Follicular Lymphoma Drugs

market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Follicular Lymphoma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Follicular Lymphoma Drugs industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Follicular Lymphoma Drugs.

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering

the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Follicular Lymphoma Drugs companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

Contents

1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 Follicular Lymphoma Drugs by Type
 - 2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
 - 1.2.2 Anti-CD20 mAbs
 - 1.2.3 Chemotherapy Agents
 - 1.2.4 Kinase Inhibitor
 - 1.2.5 Others
- 2.3 Follicular Lymphoma Drugs by Administration Route
 - 2.3.1 Market Value Comparison by Administration Route (2018 VS 2022 VS 2029)
 - 2.3.2 Injection
 - 2.3.3 Oral
- 2.4 Assumptions and Limitations

3 FOLLICULAR LYMPHOMA DRUGS BREAKDOWN DATA BY TYPE

- 3.1 Global Follicular Lymphoma Drugs Historic Market Size by Type (2018-2023)
- 3.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2023-2028)

4 FOLLICULAR LYMPHOMA DRUGS BREAKDOWN DATA BY ADMINISTRATION ROUTE

- 4.1 Global Follicular Lymphoma Drugs Historic Market Size by Administration Route (2018-2023)
- 4.2 Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2018-2023)

5 GLOBAL GROWTH TRENDS

- 5.1 Global Follicular Lymphoma Drugs Market Perspective (2018-2029)
- 5.2 Global Follicular Lymphoma Drugs Growth Trends by Region
 - 5.2.1 Global Follicular Lymphoma Drugs Market Size by Region: 2018 VS 2022 VS 2029
 - 5.2.2 Follicular Lymphoma Drugs Historic Market Size by Region (2018-2023)
 - 5.2.3 Follicular Lymphoma Drugs Forecasted Market Size by Region (2024-2029)
- 5.3 Follicular Lymphoma Drugs Market Dynamics
 - 5.3.1 Follicular Lymphoma Drugs Industry Trends
 - 5.3.2 Follicular Lymphoma Drugs Market Drivers
 - 5.3.3 Follicular Lymphoma Drugs Market Challenges
 - 5.3.4 Follicular Lymphoma Drugs Market Restraints

6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS

- 6.1 Global Top Follicular Lymphoma Drugs Players by Revenue
 - 6.1.1 Global Top Follicular Lymphoma Drugs Players by Revenue (2018-2023)
 - 6.1.2 Global Follicular Lymphoma Drugs Revenue Market Share by Players (2018-2023)
- 6.2 Global Follicular Lymphoma Drugs Industry Players Ranking, 2021 VS 2022 VS 2023
- 6.3 Global Key Players of Follicular Lymphoma Drugs Head office and Area Served
- 6.4 Global Follicular Lymphoma Drugs Players, Product Type & Application
- 6.5 Global Follicular Lymphoma Drugs Players, Date of Enter into This Industry
- 6.6 Global Follicular Lymphoma Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition

7 NORTH AMERICA

- 7.1 North America Follicular Lymphoma Drugs Market Size (2018-2029)
- 7.2 North America Follicular Lymphoma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 7.3 North America Follicular Lymphoma Drugs Market Size by Country (2018-2023)
- 7.4 North America Follicular Lymphoma Drugs Market Size by Country (2024-2029)
- 7.5 United States
- 7.6 Canada

8 EUROPE

- 8.1 Europe Follicular Lymphoma Drugs Market Size (2018-2029)
- 8.2 Europe Follicular Lymphoma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 8.3 Europe Follicular Lymphoma Drugs Market Size by Country (2018-2023)
- 8.4 Europe Follicular Lymphoma Drugs Market Size by Country (2024-2029)
- 7.4 Germany
- 7.5 France
- 7.6 U.K.
- 7.7 Italy
- 7.8 Russia
- 7.9 Nordic Countries

9 ASIA-PACIFIC

- 9.1 Asia-Pacific Follicular Lymphoma Drugs Market Size (2018-2029)
- 9.2 Asia-Pacific Follicular Lymphoma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 9.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Country (2018-2023)
- 9.4 Asia-Pacific Follicular Lymphoma Drugs Market Size by Country (2024-2029)
- 8.4 China
- 8.5 Japan
- 8.6 South Korea
- 8.7 Southeast Asia
- 8.8 India
- 8.9 Australia

10 LATIN AMERICA

- 10.1 Latin America Follicular Lymphoma Drugs Market Size (2018-2029)
- 10.2 Latin America Follicular Lymphoma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 10.3 Latin America Follicular Lymphoma Drugs Market Size by Country (2018-2023)
- 10.4 Latin America Follicular Lymphoma Drugs Market Size by Country (2024-2029)
- 9.4 Mexico
- 9.5 Brazil

11 MIDDLE EAST & AFRICA

- 11.1 Middle East & Africa Follicular Lymphoma Drugs Market Size (2018-2029)
- 11.2 Middle East & Africa Follicular Lymphoma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 11.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2018-2023)
- 11.4 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country (2024-2029)
- 10.4 Turkey
- 10.5 Saudi Arabia
- 10.6 UAE

12 PLAYERS PROFILED

- 11.1 Roche
 - 11.1.1 Roche Company Detail
 - 11.1.2 Roche Business Overview
 - 11.1.3 Roche Follicular Lymphoma Drugs Introduction
 - 11.1.4 Roche Revenue in Follicular Lymphoma Drugs Business (2017-2022)
 - 11.1.5 Roche Recent Development
- 11.2 Gilead Sciences
 - 11.2.1 Gilead Sciences Company Detail
 - 11.2.2 Gilead Sciences Business Overview
 - 11.2.3 Gilead Sciences Follicular Lymphoma Drugs Introduction
 - 11.2.4 Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2017-2022)
 - 11.2.5 Gilead Sciences Recent Development
- 11.3 TG Therapeutics
 - 11.3.1 TG Therapeutics Company Detail
 - 11.3.2 TG Therapeutics Business Overview
 - 11.3.3 TG Therapeutics Follicular Lymphoma Drugs Introduction
 - 11.3.4 TG Therapeutics Revenue in Follicular Lymphoma Drugs Business (2017-2022)
 - 11.3.5 TG Therapeutics Recent Development
- 11.4 Bayer
 - 11.4.1 Bayer Company Detail
 - 11.4.2 Bayer Business Overview
 - 11.4.3 Bayer Follicular Lymphoma Drugs Introduction
 - 11.4.4 Bayer Revenue in Follicular Lymphoma Drugs Business (2017-2022)
 - 11.4.5 Bayer Recent Development
- 11.5 Secura Bio

- 11.5.1 Secura Bio Company Detail
- 11.5.2 Secura Bio Business Overview
- 11.5.3 Secura Bio Follicular Lymphoma Drugs Introduction
- 11.5.4 Secura Bio Revenue in Follicular Lymphoma Drugs Business (2017-2022)
- 11.5.5 Secura Bio Recent Development
- 11.6 Epizyme
 - 11.6.1 Epizyme Company Detail
 - 11.6.2 Epizyme Business Overview
 - 11.6.3 Epizyme Follicular Lymphoma Drugs Introduction
 - 11.6.4 Epizyme Revenue in Follicular Lymphoma Drugs Business (2017-2022)
 - 11.6.5 Epizyme Recent Development
- 11.7 Eisai
 - 11.7.1 Eisai Company Detail
 - 11.7.2 Eisai Business Overview
 - 11.7.3 Eisai Follicular Lymphoma Drugs Introduction
 - 11.7.4 Eisai Revenue in Follicular Lymphoma Drugs Business (2017-2022)
 - 11.7.5 Eisai Recent Development
- 11.8 Acrotech Biopharma
 - 11.8.1 Acrotech Biopharma Company Detail
 - 11.8.2 Acrotech Biopharma Business Overview
 - 11.8.3 Acrotech Biopharma Follicular Lymphoma Drugs Introduction
 - 11.8.4 Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2017-2022)
 - 11.8.5 Acrotech Biopharma Recent Development
- 11.9 Teva
 - 11.9.1 Teva Company Detail
 - 11.9.2 Teva Business Overview
 - 11.9.3 Teva Follicular Lymphoma Drugs Introduction
 - 11.9.4 Teva Revenue in Follicular Lymphoma Drugs Business (2017-2022)
 - 11.9.5 Teva Recent Development
- 11.10 Eagle Pharmaceuticals
 - 11.10.1 Eagle Pharmaceuticals Company Detail
 - 11.10.2 Eagle Pharmaceuticals Business Overview
 - 11.10.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Introduction
 - 11.10.4 Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2017-2022)
 - 11.10.5 Eagle Pharmaceuticals Recent Development
- 11.11 MundiPharma
 - 11.11.1 MundiPharma Company Detail

11.11.2 MundiPharma Business Overview

11.11.3 MundiPharma Follicular Lymphoma Drugs Introduction

11.11.4 MundiPharma Revenue in Follicular Lymphoma Drugs Business (2017-2022)

11.11.5 MundiPharma Recent Development

13 REPORT CONCLUSION

14 DISCLAIMER

List Of Tables

LIST OF TABLES

Table 1. Secondary Sources

Table 2. Primary Sources

Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US\$ Million)

Table 4. Market Value Comparison by Administration Route (2018 VS 2022 VS 2029) & (US\$ Million)

Table 5. Global Follicular Lymphoma Drugs Market Size by Type (2018-2023) & (US\$ Million)

Table 6. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2018-2023)

Table 7. Global Follicular Lymphoma Drugs Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 8. Global Follicular Lymphoma Drugs Revenue Market Share by Type (2024-2029)

Table 9. Global Follicular Lymphoma Drugs Market Size by Administration Route (2018-2023) & (US\$ Million)

Table 10. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2018-2023)

Table 11. Global Follicular Lymphoma Drugs Forecasted Market Size by Administration Route (2024-2029) & (US\$ Million)

Table 12. Global Follicular Lymphoma Drugs Revenue Market Share by Administration Route (2024-2029)

Table 13. Global Follicular Lymphoma Drugs Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 14. Global Follicular Lymphoma Drugs Market Size by Region (2018-2023) & (US\$ Million)

Table 15. Global Follicular Lymphoma Drugs Market Share by Region (2018-2023)

Table 16. Global Follicular Lymphoma Drugs Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 17. Global Follicular Lymphoma Drugs Market Share by Region (2024-2029)

Table 18. Follicular Lymphoma Drugs Market Trends

Table 19. Follicular Lymphoma Drugs Market Drivers

Table 20. Follicular Lymphoma Drugs Market Challenges

Table 21. Follicular Lymphoma Drugs Market Restraints

Table 22. Global Top Follicular Lymphoma Drugs Manufacturers by Revenue (US\$ Million) & (2018-2023)

Table 23. Global Follicular Lymphoma Drugs Revenue Market Share by Manufacturers (2018-2023)

Table 24. Global Follicular Lymphoma Drugs Industry Manufacturers Ranking, 2021 VS 2022 VS 2023

Table 25. Global Key Players of Follicular Lymphoma Drugs, Headquarters and Area Served

Table 26. Global Follicular Lymphoma Drugs Manufacturers, Product Type & Application

Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 28. Global Follicular Lymphoma Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)

Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 30. North America Follicular Lymphoma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 31. North America Follicular Lymphoma Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 32. North America Follicular Lymphoma Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 33. Europe Follicular Lymphoma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 34. Europe Follicular Lymphoma Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 35. Europe Follicular Lymphoma Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 36. Asia-Pacific Follicular Lymphoma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 37. Asia-Pacific Follicular Lymphoma Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 38. Asia-Pacific Follicular Lymphoma Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 39. Latin America Follicular Lymphoma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 40. Latin America Follicular Lymphoma Drugs Market Size by Country (2018-2023) & (US\$ Million)

Table 41. Latin America Follicular Lymphoma Drugs Market Size by Country (2024-2029) & (US\$ Million)

Table 42. Middle East & Africa Follicular Lymphoma Drugs Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 43. Middle East & Africa Follicular Lymphoma Drugs Market Size by Country

(2018-2023) & (US\$ Million)

Table 44. Middle East & Africa Follicular Lymphoma Drugs Market Size by Country

(2024-2029) & (US\$ Million)

Table 45. Roche Company Detail

Table 46. Roche Business Overview

Table 47. Roche Follicular Lymphoma Drugs Product

Table 48. Roche Revenue in Follicular Lymphoma Drugs Business (2017-2022) & (US\$ Million)

Table 49. Roche Recent Development

Table 50. Gilead Sciences Company Detail

Table 51. Gilead Sciences Business Overview

Table 52. Gilead Sciences Follicular Lymphoma Drugs Product

Table 53. Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2017-2022) & (US\$ Million)

Table 54. Gilead Sciences Recent Development

Table 55. TG Therapeutics Company Detail

Table 56. TG Therapeutics Business Overview

Table 57. TG Therapeutics Follicular Lymphoma Drugs Product

Table 58. TG Therapeutics Revenue in Follicular Lymphoma Drugs Business (2017-2022) & (US\$ Million)

Table 59. TG Therapeutics Recent Development

Table 60. Bayer Company Detail

Table 61. Bayer Business Overview

Table 62. Bayer Follicular Lymphoma Drugs Product

Table 63. Bayer Revenue in Follicular Lymphoma Drugs Business (2017-2022) & (US\$ Million)

Table 64. Bayer Recent Development

Table 65. Secura Bio Company Detail

Table 66. Secura Bio Business Overview

Table 67. Secura Bio Follicular Lymphoma Drugs Product

Table 68. Secura Bio Revenue in Follicular Lymphoma Drugs Business (2017-2022) & (US\$ Million)

Table 69. Secura Bio Recent Development

Table 70. Epizyme Company Detail

Table 71. Epizyme Business Overview

Table 72. Epizyme Follicular Lymphoma Drugs Product

Table 73. Epizyme Revenue in Follicular Lymphoma Drugs Business (2017-2022) & (US\$ Million)

Table 74. Epizyme Recent Development

- Table 75. Eisai Company Detail
- Table 76. Eisai Business Overview
- Table 77. Eisai Follicular Lymphoma Drugs Product
- Table 78. Eisai Revenue in Follicular Lymphoma Drugs Business (2017-2022) & (US\$ Million)
- Table 79. Eisai Recent Development
- Table 80. Acrotech Biopharma Company Detail
- Table 81. Acrotech Biopharma Business Overview
- Table 82. Acrotech Biopharma Follicular Lymphoma Drugs Product
- Table 83. Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2017-2022) & (US\$ Million)
- Table 84. Acrotech Biopharma Recent Development
- Table 85. Teva Company Detail
- Table 86. Teva Business Overview
- Table 87. Teva Follicular Lymphoma Drugs Product
- Table 88. Teva Revenue in Follicular Lymphoma Drugs Business (2017-2022) & (US\$ Million)
- Table 89. Teva Recent Development
- Table 90. Eagle Pharmaceuticals Company Detail
- Table 91. Eagle Pharmaceuticals Business Overview
- Table 92. Eagle Pharmaceuticals Follicular Lymphoma Drugs Product
- Table 93. Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2017-2022) & (US\$ Million)
- Table 94. Eagle Pharmaceuticals Recent Development
- Table 95. MundiPharma Company Detail
- Table 96. MundiPharma Business Overview
- Table 97. MundiPharma Follicular Lymphoma Drugs Product
- Table 98. MundiPharma Revenue in Follicular Lymphoma Drugs Business (2017-2022) & (US\$ Million)
- Table 99. MundiPharma Recent Development
- Table 100. Roche Company Information
- Table 101. Roche Business Overview
- Table 102. Roche Follicular Lymphoma Drugs Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million)
- Table 103. Roche Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 104. Roche Recent Development
- Table 105. Gilead Sciences Company Information
- Table 106. Gilead Sciences Business Overview

- Table 107. Gilead Sciences Follicular Lymphoma Drugs Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million)
- Table 108. Gilead Sciences Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 109. Gilead Sciences Recent Development
- Table 110. TG Therapeutics Company Information
- Table 111. TG Therapeutics Business Overview
- Table 112. TG Therapeutics Follicular Lymphoma Drugs Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million)
- Table 113. TG Therapeutics Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 114. TG Therapeutics Recent Development
- Table 115. Bayer Company Information
- Table 116. Bayer Business Overview
- Table 117. Bayer Follicular Lymphoma Drugs Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million)
- Table 118. Bayer Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 119. Bayer Recent Development
- Table 120. Secura Bio Company Information
- Table 121. Secura Bio Business Overview
- Table 122. Secura Bio Follicular Lymphoma Drugs Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million)
- Table 123. Secura Bio Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 124. Secura Bio Recent Development
- Table 125. Epizyme Company Information
- Table 126. Epizyme Business Overview
- Table 127. Epizyme Follicular Lymphoma Drugs Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million)
- Table 128. Epizyme Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million) Portfolio
- Table 129. Epizyme Recent Development
- Table 130. Eisai Company Information
- Table 131. Eisai Business Overview
- Table 132. Eisai Follicular Lymphoma Drugs Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million)
- Table 133. Eisai Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 134. Eisai Recent Development

Table 135. Acrotech Biopharma Company Information

Table 136. Acrotech Biopharma Business Overview

Table 137. Acrotech Biopharma Follicular Lymphoma Drugs Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million)

Table 138. Acrotech Biopharma Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 139. Acrotech Biopharma Recent Development

Table 140. Teva Company Information

Table 141. Teva Business Overview

Table 142. Teva Follicular Lymphoma Drugs Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million)

Table 143. Teva Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 144. Teva Recent Development

Table 145. Eagle Pharmaceuticals Company Information

Table 146. Eagle Pharmaceuticals Business Overview

Table 147. Eagle Pharmaceuticals Follicular Lymphoma Drugs Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million)

Table 148. Eagle Pharmaceuticals Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million) Portfolio

Table 149. Eagle Pharmaceuticals Recent Development

Table 150. MundiPharma Company Information

Table 151. MundiPharma Business Overview

Table 152. MundiPharma Follicular Lymphoma Drugs Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million)

Table 153. MundiPharma Revenue in Follicular Lymphoma Drugs Business (2018-2023) & (US\$ Million) Portfolio

I would like to order

Product name: Follicular Lymphoma Drugs Industry Research Report 2023

Product link: <https://marketpublishers.com/r/F1051D5E19D8EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F1051D5E19D8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970